Hong Kong WinHealth Pharma Group (WinHealth Pharma) and Guangdong Rongtai Pharmaceutical Co., Ltd. (Rongtai Pharmaceutical) recently entered into a strategic partnership, laying a solid foundation for long-term collaboration between the two companies. Both parties will work together in key areas such as digital transformation, the development of diversified commercial channels, market expansion, and industry collaboration. By leveraging WinHealth Pharma’s unique strengths in commercial strategy and Rongtai Pharmaceutical’s expertise in channel integration and market expansion, both parties aim to jointly create an open, mutually beneficial industry ecosystem and accelerate the market access of innovative therapies and originator medicines in the Chinese market. The signing ceremony was witnessed by Jack Wang, Chairman of WinHealth Pharma, Changqing Chen, Chairman of Rongtai Pharmaceutical, Haifeng Zhao, Chairman of Hong Kong Kanghong Pharmaceutical Group, along with key members of both management teams.
Management teams from WinHealth Pharma and Rongtai Pharmaceutical at the Signing Ceremony
Rongtai Pharmaceutical is a leading provider of integrated pharmaceutical services, specializing in online pharmacy platforms for both pharmacists and patients, supported by a comprehensive distribution system. With its advanced online marketing capabilities, platform strengths, and extensive nationwide channel network, Rongtai Pharmaceutical delivers tailored operational solutions to pharmaceutical companies, establishing a significant presence in the non-hospital market. Through this collaboration, WinHealth Pharma will leverage Rongtai Pharmaceutical’s robust online infrastructure and market coverage to accelerate the nationwide expansion of innovative therapies and originator medicines, improving patient access and overall experiences. At the same time, Rongtai will enrich its portfolio with more innovative and competitive products, further strengthening its market position.
Jack Wang, Chairman of WinHealth Pharma, said:
"WinHealth Pharma has always adhered to the founding principle of putting patients first. This strategic partnership with Rongtai Pharmaceutical marks a meaningful step forward in advancing innovative business models and accelerating our digital transformation. By leveraging Rongtai Pharmaceutical’s unique strengths in online channel reach and service capabilities, we will further accelerate the development of new commercial models and drive progress across the healthcare ecosystem, broadening access by more precisely delivering therapies to the patients who need them most. Through high-level strategic collaboration, both companies will work together to build an open and mutually beneficial ecosystem, expand access to originator and innovative therapies in the Chinese market, and contribute to the realization of the 'Healthy China 2030' vision—ultimately improving outcomes for more patients."
Changqing Chen, Chairman of Rongtai Pharmaceutical, said:
“Grounded in our strengths in digital pharmaceutical retail and online marketing, the partnership with WinHealth Pharma enables a full value chain upgrade — from product introduction and channel penetration to patient-facing services. We look forward to working together to fully leverage the strengths of both parties, further optimizing the non-hospital market, enhancing the patient experience and medication adherence, and contribute to the sustainable growth of the pharmaceutical industry."
This strategic partnership builds on both parties’ deep insights into industry trends and a clear understanding of the commercial landscape. By leveraging their respective strengths, the two companies aim to jointly drive innovation and transformation across the pharmaceutical sector, delivering high-quality medicines and exceptional services to patients. Moving forward, both parties will continue to deepen collaboration, unlock new growth opportunities, and contribute to the long-term advancement of China’s pharmaceutical sector.
About Rongtai Pharmaceutical
Founded in 2004, Guangdong Rongtai Pharmaceutical Co., Ltd. is a leading provider of integrated pharmaceutical services in China, specializing in digital pharmacy operations and supported by a nationwide distribution network. Leveraging its strong digital marketing capabilities and platform management expertise, the company has built a comprehensive model that combines full-network operations with full-network distribution. With a focus on improving patient access, medication adherence, and brand visibility, Rongtai pharmaceutical delivers customized commercial and marketing solutions for a broad range of industry partners through S2B2C, S2B2b, and S2C models. The company has established strategic partnerships with many leading multinational and domestic pharmaceutical companies, driving commercial success and sustainable growth for its partners.
About WinHealth Pharma
WinHealth Pharma is a China-based integrated pharmaceutical company with a core focus on kidney diseases and strategic expansion into hematology and other major therapeutic areas. It possesses comprehensive capabilities across the entire pharmaceutical value chain from research and development to manufacturing and commercialization. Guided by its “Patients-First” philosophy and the mission of “Advancing Health, Empowering Lives,” the company is dedicated to improving patients' quality of life through innovative therapies. By leveraging a multi-strategy-driven business model, WinHealth Pharma connects with global innovations to continuously build a diverse, differentiated, and highly competitive product portfolio. Anchoring a strong presence in China, the company is actively expanding into other Asian markets and key international regions, including Switzerland and Japan. WinHealth Pharma is committed to fostering an open and collaborative healthcare ecosystem, driving industry innovation to meet the evolving needs of patients worldwide. For more information, please visit www.winhealth.hk.